MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Bristol-Myers Squibb Co.

Closed

SectorHealthcare

48.68 0.35

Overview

Share price change

24h

Current

Min

46.98

Max

48.84

Key metrics

By Trading Economics

Income

-1.1B

76M

Sales

442M

12B

P/E

Sector Avg

14.05

57.333

EPS

1.67

Dividend yield

5.04

Profit margin

0.616

Employees

34,100

EBITDA

-1.9B

2.6B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+17.72% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

5.04%

2.63%

Next Dividend date

1 maj 2025

Next Ex Dividend date

4 lip 2025

Market Stats

By TradingEconomics

Market Cap

-21B

100B

Previous open

48.33

Previous close

48.68

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Bristol-Myers Squibb Co. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2025, 11:32 UTC

Earnings

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

11 mar 2025, 10:13 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 mar 2025, 10:13 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

24 kwi 2025, 21:24 UTC

Earnings

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 kwi 2025, 14:15 UTC

Top News
Earnings

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 kwi 2025, 12:37 UTC

Market Talk
Earnings

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24 kwi 2025, 11:17 UTC

Earnings

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24 kwi 2025, 11:13 UTC

Top News
Earnings

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20% to $5.64B >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Adj EPS $1.80 >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B Vs Prior View $45.5B >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Gross Margin 72.9% >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70-Adj EPS $7.00 Vs Prior View $6.55-$6.85 >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q Rev $11.2B >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 1Q EPS $1.20 >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol-Myers Squibb 1Q Adj EPS $1.80 >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol-Myers Squibb 1Q Rev $11.2B >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol-Myers Squibb 1Q Net $2.46B >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol-Myers Squibb Sees FY Adj EPS $6.70-Adj EPS $7.00 >BMY

24 kwi 2025, 10:59 UTC

Earnings

Bristol-Myers Squibb 1Q EPS $1.20 >BMY

14 mar 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Peer Comparison

Price change

Bristol-Myers Squibb Co. Forecast

Price Target

By TipRanks

17.72% upside

12 Months Forecast

Average 57.13 USD  17.72%

High 70 USD

Low 36 USD

Based on 18 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

18 ratings

5

Buy

12

Hold

1

Sell

Technical Score

By Trading Central

48.16 / 48.82Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.